NEW YORK – Foundation Medicine said on Wednesday that the US Food and Drug Administration has approved its FoundationOne CDx test as a companion diagnostic for alpelisib (Novartis' Piqray) in combination with fulvestrant (AstraZeneca's Faslodex) for the treatment of postmenopausal women, as well as men, with hormone receptor-positive, human epidermal growth factor receptor 2-negative, PIK3CA-mutated, advanced or metastatic breast cancer following progression on or after an endocrine-based treatment.
To read the full story....
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.